Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEGMI-QOL trial of adding imeglimin after reducing bolus insulin in type 2 diabetes
jRCT1011240025Recruiting
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of imeglimin and human insulin in type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoint: Change from baseline in DTSQs total score at 12 weeks. Started Nov 2024; status: recruiting.
02
Drugs
imegliminhuman insulin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1011240025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1011240025.